Skip to main content


ASH 2018 Meeting and Exposition

November 29, 2018

December 1-4 marked the annual American Society of Hematology (ASH) Annual Meeting and Exposition. Leading experts convened in San Diego, CA to dive in and address the latest news and research updates in malignant and non-malignant hematology.

Early Resource Utilization Associated With CAR-T Infusion for Hematologic Malignancies

CAR-T therapy utilizes resources across the therapeutic spectrum; increased use of this therapy may create challenges in institutional resource capacity, according to new research. 

Read the full article


Prognostic Testing, Treatment Approaches in Patients With CLL

A study sheds light on a “considerable lack” of prognostic marker testing among patients with CLL in the modern era. 

Read the full article



Daratumumab Plus Lenalidomide and Dexamethasone Effective in Newly Diagnosed Myeloma

The addition of daratumumab to conventional therapy for transplant-ineligible, newly diagnosed multiple myeloma patients reduces the risk of progression or death by 44%.

Read the full article



AML Precision Medicine Test Predicts Response to Therapy Faster Than Cytogenetics

The PharmaFlow Precision Medicine Test provides similar information, yet is faster than conventional cytogenetics in predicting response to therapy in patients with AML, according to new research. 

Read the full article


Treatment Decision-Making in CLL: The Patient Perspective

A survey showed that most patients with CLL want to be involved in therapy decisions and that gender, age, and therapy status influence decision-making. 

Read the full article


NCCN-Recommended Triplet Regimens Compared in Newly Diagnosed Multiple Myeloma

Triplet regimens incorporating a proteasome inhibitor and an immunomodulatory drug for the treatment of newly diagnosed multiple myeloma were compared for relative effectiveness and tolerability.

Read the full article


CAR-T Cost-Effectiveness, Health Outcomes Relative to Past Innovative Cancer Treatments

A recent study sought to determine whether CAR-T therapy aligned with the recent trend of negligible incremental effectiveness and rising cost per life-year gained of other innovative cancer treatments. 

Read the full article


Does HCT Offer Benefit Over Non-HCT Therapies in Patients With AML?

Improvement in supportive care and non-HCT therapies, along with other variables, may contribute to similar benefit of HCT and non-HCT therapies in patients with AML. 

Read the full article


Real-World Outcomes of CAR-T Therapy as Standard of Care

A retrospective study assessed whether responses to CAR-T therapy in the real world are comparable to the best responses observed in the ZUMA-1 clinical trial. 

Read the full article


Targeted Therapy Particularly Promising in Certain Patients With Relapsed or Refractory AML

Gemtuzumab ozogamicin is safe for patients with AML and APL, but combinations of the drug may be better suited for relapsed or refractory AML with measurable residual disease.

Read the full article

Back to Top